The French Competition Authority dismisses allegation of abuse against a pharmaceutical company (Sanofi-Aventis)

In a recently published decision of 14 January 2010, the French Competition Authority dismissed the allegation of the French Minister for the Economy against Sanofi-Aventis (“Sanofi”) concerning that firm’s pricing practices on the market for the supply of low-molecular-weight heparins (“LMWHs”) to hospitals. LMWHs are anticoagulants used to treat and prevent thrombosis. On 7 July 2006, the Minister for the Economy alleged that Sanofi‘s free supplies of LMWHs to hospitals for use in preventing thrombosis

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Practising Law Institute (New York)

Quotation

Tim Kasten, Sean Gerlich, The French Competition Authority dismisses allegation of abuse against a pharmaceutical company (Sanofi-Aventis), 14 January 2010, e-Competitions Bulletin January 2010, Art. N° 41645

Visites 187

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues